First Manhattan
DRNA

First Manhattan’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

First Manhattan’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-428,100
Closed -$4.09M – 1442
2018
Q1 		$4.09M Hold
428,100
– – 0.02% 276
2017
Q4 		$3.87M Buy
+428,100
New +$3.15M 0.02% 295

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan's DRNA Position: Q2 2018 in Review

First Manhattan sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2018, closing a stake of 428,100 shares — an estimated $4.09M sold.

First Manhattan first reported a position in DRNA in Q4 2017 and held it in 2 quarters. The position peaked at $4.09M in Q1 2018. 85 funds tracked by Wall St. Rank hold DRNA as of Q2 2018.

  • First Manhattan reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • First Manhattan sold 428,100 Dicerna Pharmaceuticals, Inc. shares in Q2 2018, an estimated $4.09M.
  • First Manhattan first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • First Manhattan's Dicerna Pharmaceuticals, Inc. position peaked at $4.09M in Q1 2018.
  • 85 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2018.

Based on First Manhattan's 13F filing for Q2 2018, filed 1 Aug 2018.